Cytokinetics, Inc. (NASDAQ:CYTK) disclosed a recent transaction involving EVP of Research and Development, Malik Fady Ibraham, selling shares of the company’s common stock. On June 25, 2024, Ibraham sold a total of 7,300 shares at prices between $53.71 and $53.74, with a total value of approximately $392,143.
The transaction was part of a series of options sales and exercises reported by the executive on the same day. In addition to the shares sold, Ibraham also exercised options to purchase 5,300 shares of Cytokinetics common stock at a price of $7.96 per share, for a total of $42,188. Following these transactions, Ibraham’s direct ownership in the company is 133,004 shares.
Cytokinetics, headquartered in South San Francisco, California, specializes in pharmaceutical preparations and is actively engaged in the development of therapies that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Investors and followers of Cytokinetics will likely keep an eye on insider transactions like this to get a sense of executive sentiment and the potential impact on the company’s stock performance.
This article was generated and translated with the support of artificial intelligence and reviewed by an editor. For further information, please see our T&Cs.
